IMPA2

Across TCGA pan-cancer cohorts, IMPA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IMPA2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IMPA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IMPA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where IMPA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.947	0.726	<.001	47	view →
PDAC	DFS	Quartile	II,III,IV	0.509	0.246	.005	24	view →
HNSC	DFS	Median	II,III,IV	0.770	0.571	.020	11	view →
LUAD	DFS	Tertile	All	0.953	0.620	.012	5	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IMPA2–CCRCC (OS)

Open the CCRCC breakdown →